Overview
Eugene John Vaios, MD, MBA, is an NIH-funded Assistant Professor of Radiation Oncology at the Duke Cancer Institute. He was previously at Harvard University where he completed his undergraduate and graduate education, as well as his internship at Cambridge Health Alliance. Eugene's research focus is at the intersection of radiation therapy and immunotherapy for patients with primary and metastatic brain tumors. Active translational research includes the development of a liquid biopsy for non-invasive diagnosis, surveillance, and prediction of treatment response in patients with brain tumors. Other interests include leveraging artificial intelligence and big data to improve cancer outcomes. Outside Duke, Eugene holds leadership positions on the ASTRO Board Finance and Audit Committee and serves on the Lancet Commission on Neurorehabilitation.
Current Appointments & Affiliations
Recent Publications
Identifying predictive factors for radiation necrosis vs local recurrence in biopsy-proven enlarging lesions post-stereotactic radiosurgery for brain metastases
Journal Article Neuro-Oncology Practice · December 10, 2025 AbstractBackgroundStereotactic radiosurgery (SRS) remains the standard of care for brain metastases (BM), offering effective lo ... Full text CiteNeurocognitive outcomes in patients with brain metastases: a systematic review.
Journal Article Lancet Oncol · December 2025 Multimodality therapy, including surgery, radiotherapy, and systemic therapy, has significantly improved overall survival for patients with brain metastases. However, treatment-related neurocognitive sequelae remain a major challenge in survivorship. Altho ... Full text Link to item CiteManagement outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade.
Journal Article J Neurooncol · October 2025 PURPOSE: Immunotherapy and stereotactic radiosurgery (SRS) are frequently combined in the management of brain metastases from non-small cell lung cancer (NSCLC) and melanoma. However, concurrent SRS and dual immune-checkpoint inhibition (ICPI) elevate the ... Full text Open Access Link to item CiteRecent Grants
Elucidating Brain Tumor Biology and Response to Radiotherapy Using Cell-Free-DNA Methylation Signatures
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2026View All Grants